nanotech investing Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
nanotech investing Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association Annual Meeting
nanotech investing Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
nanotech investing Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
nanotech investing Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
nanotech investing Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
nanotech investing Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
nanotech investing Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma
nanotech investing Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel , an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies
nanotech investing Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma
nanotech investing Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference
nanotech investing Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update
The Crushed Pile in Nevada: How a Forgotten 1989 Gold Heap Is Becoming One of America's Few Near-Term Antimony Solutions
